MedTrace Logo

Pembrolizumab In Central Nervous System Metastases

NCT02886585 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2024-03-12

No results posted yet for this study

Summary

This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).

Conditions

Interventions

DRUG

Pembrolizumab

RADIATION

MRI

RADIATION

PET/CT

PROCEDURE

Stereotactic Radiosurgery

Sponsors & Collaborators

Principal Investigators

  • Priscilla Brastianos, MD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02886585 on ClinicalTrials.gov